Bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
There were many investigations, both theoretical and experimental, trying to determine the transition energy precisely and to specify other properties of the isomeric state of 229Th (such as its lifetime and magnetic moment), until the frequency was accurately measured in 2024. The first prototype nuclear clocks were announced in June 2026.
Metformin - widely used in treatment of diabetes mellitus type 2 Phenformin - withdrawn from the market in most countries due to toxic effects Buformin - withdrawn from the market due to toxic effects
=== Hemoglobin synthesis and function === PLP aids in the synthesis of hemoglobin, by serving as a coenzyme for the enzyme aminolevulinic acid synthase. It also binds to two sites on hemoglobin to enhance the oxygen binding of hemoglobin.
Modeled on Europe's Christkindlmarkt, in 2002 Bryant Park introduced the Holiday Shops in an effort to liven up the park space during the winter. Initially slow to gain traction, the Holiday Shops became a fixture of the Manhattan holiday scene in 2005 by adding an ice-skating rink. The Shops also include a Norway Spruce tree, as well as a standalone dining and event space. Sponsored by Bank of America, Winter Village can be set up within two weeks. In September 2016, Bryant Park Corporation announced market makers Urbanspace as the new operator for the Holiday Shops, which grew from 80 boutiques in 2002 to over 170 in 2018. In 2018, Urbanspace also took over management of the rinkside eatery, rebranding it as The Lodge. The Gothamist wrote in 2024 that visitors had mixed views of Winter Village; though tourists and some New Yorkers liked Winter Village's shops and food stands, detractors felt that the shops were overcrowded.
Sources: en.wikipedia.org
Overnutrition caused by overeating is also a form of malnutrition. In the United States, more than half of all adults are now overweight—a condition that, like hunger, increases susceptibility to disease and disability, reduces worker productivity, and lowers life expectancy. Overeating is much more common in the United States, since most people have adequate access to food. Many parts of the world have access to a surplus of non-nutritious food. Increased sedentary lifestyles also contribute to overnutrition. Yale University psychologist Kelly Brownell calls this a "toxic food environment", where fat- and sugar-laden foods have taken precedence over healthy nutritious foods. In these developed countries, overnutrition can be prevented by choosing the right kind of food. More fast food is consumed per capita in the United States than in any other country. This mass consumption of fast food results from its affordability and accessibility. Fast food, which is low in cost and nutrition, is high in calories. Due to increasing urbanization and automation, people are living more sedentary lifestyles. These factors combine to make weight gain difficult to avoid. Overnutrition also occurs in developing countries. It has appeared in parts of developing countries where income is on the rise. It is also a problem in countries where hunger and poverty persist. Economic development, rapid urbanisation and shifting dietary patterns have increased the burden of overnutrition in the cities of low and middle-income countries.
Early Norman kings of England, as Dukes of Normandy, owed homage to the King of France for their land on the continent. They considered England to be their most important holding (it brought with it the title of King—an important status symbol). While in England, locals often referred to the Normans as Franci. Eventually, the Normans merged with the natives, combining languages and traditions, so much so that Marjorie Chibnall says "writers still referred to Normans and English; but the terms no longer meant the same as in the immediate aftermath of 1066." In the course of the Hundred Years' War, the Norman aristocracy often identified themselves as English. The Anglo-Norman language became distinct from the French spoken in Paris, something that was the subject of some humour by Geoffrey Chaucer. The Anglo-Norman language was eventually absorbed into the Anglo-Saxon language of their subjects (see Old English) and influenced it, helping (along with the Norse language of the earlier Anglo-Norse settlers and the Latin used by the church) in the development of Middle English, which, in turn, evolved into Modern English.
Recent data show that astrocytes function as glucose sensors and exert a commanding influence upon neuronal reactivity to changes in extracellular glucose. GP astrocytes possess high-capacity GLUT2-type glucose transporter proteins and appear to modulate the neuronal responses to glucose. Hypothalamic cells monitor blood levels of glucose and exert an influence upon blood glucose levels via an altered input to autonomic circuits that innervate liver and muscle cells. The importance of astrocytes in aging-related disturbances in glucose metabolism has been recently illustrated by studies of diabetic animals. A single infusion of a protein called fibroblast growth factor-1 into the hypothalamus has been shown to permanently normalize blood glucose levels in diabetic rodents. This remarkable cure of diabetes mellitus is mediated by astrocytes. The most prominent genes activated by FGF-1 treatment include the genes responsible for the synthesis of FABP6 and FABP7 by astrocytes. These data confirm the importance of FABP7+ astrocytes for the control of blood glucose. Dysfunction of FABP7+/Gomori-positive astrocytes may contribute to the aging-related development of diabetes mellitus. GP astrocytes are also present in the dentate gyrus of the hippocampus in both rodent and human brains. The hippocampus undergoes severe degenerative changes during aging in Alzheimer's disease. The reasons for these degenerative changes are currently being hotly debated. A recent study has shown that levels of glial proteins, and NOT neuronal proteins, are most abnormal in Alzheimer's disease.
==== DX-9065a binding to factor Xa ==== DX-9065a, the first small molecule direct Xa-inhibitor, is an amidinoaryl derivate with a molecular weight of 571.07g/mol. Its positively charged amidinonaphtalene group forms a salt bridge to the Asp-189 residue in the S1 pocket of FXa. The pyrrolidine ring fits between Tyr-99, Phe-174 and Trp-215 in the S4 pocket of FXa.
The Bristol stool scale is a diagnostic medical tool designed to classify the form of human faeces into seven categories. It is used in both clinical and experimental fields. It was developed at the Bristol Royal Infirmary as a clinical assessment tool in 1997, by Stephen Lewis and Ken Heaton and is widely used as a research tool to evaluate the effectiveness of treatments for various diseases of the bowel, as well as a clinical communication aid; including being part of the diagnostic triad for irritable bowel syndrome.
Sources: en.wikipedia.org
Donald F. Hunt is the University Professor of Chemistry and Pathology at the University of Virginia. He is known for his research in the field of mass spectrometry, he developed electron capture negative ion mass spectrometry. He has received multiple awards for his work including the Distinguished Contribution Award from the American Society for Mass Spectrometry and the Thomson Medal from the International Mass Spectrometry Society.
In August 2010, James Brokenshire, the Home Office drugs minister, announced plans to create a new category in the Misuse of Drugs Act, through the Police Reform and Social Responsibility Bill, that would allow new legal highs to be made temporarily illegal, without the need for a vote in parliament or advice from the ACMD, as was required to categorise mephedrone. According to the Independent Scientific Committee on Drugs, after mephedrone was made illegal, a street trade in the drug emerged, with prices around double those prior to the ban, at £20–£25 per gram. In September 2010, Druglink reported the ban had a mixed effect on mephedrone use, with it decreasing in some areas, remaining similar in others, and becoming more prevalent in some areas. In an online survey of 150 users after the ban, 63% said they were continuing to use mephedrone; of those, half claimed unchanged usage amounts (as to dosage and frequency), and half claimed decreased usage. Compared to previous surveys, more users purchased it from dealers, rather than the internet. The average price per gram was £16, compared to around £10 before the ban. The 2010 Mixmag survey of 2,500 nightclubbers found one quarter had used mephedrone in the previous month, the price had roughly doubled since it was made illegal, and it was more likely to be cut with other substances. Of those who had already used mephedrone prior to the ban, 75% had continued to use it after the ban. Of the various drugs used by the survey participants, users were more likely to have concerns about it.
== Protactinium-230 == Protactinium-230 has 139 neutrons and a half-life of 17.4 days. Most of the time (92%), it undergoes beta plus decay to 230Th, with a smaller (8%) beta-minus decay branch leading to 230U. It also has a very rare (0.0032%) alpha decay mode leading to 226Ac. It is not found in nature because its half-life is short and it is not found in the decay chains of 235U, 238U, or 232Th. Protactinium-230 is of interest as a progenitor of uranium-230, an isotope that has been considered for use in targeted alpha-particle therapy (TAT). It can be produced through proton or deuteron irradiation of natural thorium.
Dorian Andrew Mientjez Yates (born 19 April 1962) is an English retired professional bodybuilder and a six-time Mr. Olympia champion. He won the title consecutively from 1992 to 1997 and became known by the nickname "The Shadow" for his discreet approach to competition, often appearing at major events without prior public confirmation. Between contests, Yates maintained a low public profile. This also contributed to his distinctive reputation within bodybuilding. Known for his impressive conditioning and wide and thick back, he is regarded as one of the greatest professional bodybuilders of all time. Influenced by the concepts of Mike Mentzer, Yates is credited with popularising high-intensity training (HIT) in the 1990s. He was inducted into the IFBB Hall of Fame in 2003.
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.